New research from the Indiana University School of Medicine.

Research shows people previously vaccinated against mpox in 2022 had declining antibody responses after six to 12 months, as World Health Organization (WHO) designates the 2024...

Healthcare providers in the U.S. face major challenges in achieving high vaccination rates against COVID-19, RSV and influenza.

More than 95% of the 660,000 cervical cancer cases occurring globally each year are caused by HPV.

NCDs are posted on the CMS Medicare Coverage Center website and provide stakeholders with the Medicare coverage criteria for each technology, a summary of the evidence considered...

Overall breast cancer mortality rates are dropping.

Risk to the general public still remains low.

RSV is of greatest concern in young children, the elderly and adults at high risk for respiratory complications.

Roswell Park’s Dr. Eunice Wang led KOMET-001 clinical trial; results newly reported in The Lancet Oncology.

I-SPY 2.2 study finds early breast cancer patients may benefit from pre-surgery combination of antibody drug conjugate Dato-DXd and checkpoint inhibitor durvalumab.